Allogene Therapeutics, Inc.
ALLO
$2.13
$0.073.40%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -36.25% | -36.33% | -30.30% | -20.25% | -3.94% |
| Gross Profit | 36.25% | 36.33% | 30.30% | 20.25% | 3.90% |
| SG&A Expenses | -6.02% | -11.25% | -15.89% | -11.23% | -13.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.30% | -29.90% | -26.45% | -18.07% | -6.24% |
| Operating Income | 29.30% | 29.90% | 26.45% | 18.07% | 6.21% |
| Income Before Tax | 28.67% | 34.77% | 37.55% | 23.23% | 8.10% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 28.67% | 35.25% | 37.55% | 23.23% | 8.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 28.67% | 35.25% | 37.55% | 23.23% | 8.10% |
| EBIT | 29.30% | 29.90% | 26.45% | 18.07% | 6.21% |
| EBITDA | 30.39% | 31.28% | 27.72% | 18.26% | 5.85% |
| EPS Basic | 36.09% | 39.67% | 41.15% | 33.36% | 27.82% |
| Normalized Basic EPS | 36.10% | 37.18% | 29.82% | 31.32% | 27.81% |
| EPS Diluted | 36.09% | 39.67% | 41.15% | 33.36% | 27.82% |
| Normalized Diluted EPS | 36.10% | 37.18% | 29.82% | 31.32% | 27.81% |
| Average Basic Shares Outstanding | 11.58% | 7.34% | 6.14% | 15.21% | 27.33% |
| Average Diluted Shares Outstanding | 11.58% | 7.34% | 6.14% | 15.21% | 27.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |